Induction of long-lasting immunity against viral respiratory tract infections remains an elusive goal. Using a nonhuman primate model of human respiratory syncytial virus (hRSV) infection, we compared mucosal and systemic immune responses induced by different DNA delivery approaches to a novel parenteral DNA prime-tonsillar adenoviral vector booster immunization regimen. Intramuscular (i.m.) electroporation (EP) of a DNA vaccine encoding the fusion protein of hRSV induced stronger systemic immune responses than intradermal EP, tattoo immunization, and conventional i.m. DNA injection. A single EP i.m., followed by two atraumatic tonsillar immunizations with the adenoviral vector, elicited strong systemic immune responses, an unique persistent CD4+ and CD8+ T cell response in the lower respiratory tract and protection from intranasal hRSV challenge. Thus, parenteral DNA priming followed by booster immunization targeted to a mucosal inductive site constitutes an effective vaccine regimen for eliciting protective immune responses at mucosal effector sites.

Additional Metadata
Persistent URL,
Journal Journal of Virology
Grunwald, T, Tenbusch, M, Schulte, R, Raue, K, Wolf, H, Hannaman, D, … Stahl-Hennig, C. (2014). Novel vaccine regimen elicits strong airway immune responses and control of respiratory syncytial virus in nonhuman primates. Journal of Virology, 88(8), 3997–4007. doi:10.1128/JVI.02736-13